Julia A. Gaebler

Julia A. Gaebler has a diverse work experience in the healthcare industry. Julia is currently serving as the Chief Business Officer at Lucy Therapeutics. Prior to this, they held the role of Independent Director at Atlas5D since 2016. From 2021 to 2022, Julia was the VP of Commercial Strategy & Portfolio Planning at Milestone Pharmaceuticals, Inc. Julia also worked at Health Advances, a global strategy consulting firm focused on healthcare, where they held the positions of Partner from 2017 to 2021 and Vice President from 2014 to 2017. Prior to that, they worked at Biogen Idec as the Senior Director of Global Medical Affairs and the Director of Commercial Operations, Global Market Access from 2011 to 2014. Julia also has experience at Amylin Pharmaceuticals and Roche Pharmaceuticals, where they held various roles related to medical affairs, pricing, policy research, and research and development. Julia'searly experience includes working as a Full Policy Researcher and Associate Policy Researcher at RAND Corporation from 2004 to 2008.

Julia A. Gaebler holds a PhD in Health Policy with a Concentration in Decision Sciences, which they obtained from Harvard University between 1999 and 2004. Prior to their doctoral studies, they earned a Master of Arts (MA) degree in International Economics & European Studies from the Johns Hopkins School of Advanced International Studies (SAIS) from 1993 to 1995. Julia'sundergraduate education took place at the University of Pennsylvania, where they received a Bachelor of Arts (BA) degree in European Intellectual History from 1987 to 1991. Before entering college, Julia attended The Sidwell Friends School, although no specific degree or field of study was mentioned for this stage of their education.